PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
16571104-0	2006	Dihydroceramide:sphinganine C-4-hydroxylation requires Des2 hydroxylase and the membrane form of cytochrome b5.	dihydroceramide	0-15	complement component 4B (Chido blood group)	Mus musculus	28-31
19703775-3	2009	Compared with their corresponding 4-hydroxy compounds, these derivatives exhibited slight improvement on their inhibitory potency, but still much weaker than their corresponding compounds with no substituents at the C-4 of the pyrrolidine moiety, with the most potent affinity being about 1/15 fold as that of Tiagabine.	pyrrolidine	227-238	complement component 4B (Chido blood group)	Mus musculus	216-219
19703775-5	2009	However the configuration of the C-4 linking fluorine did not have much influence on their affinity for GAT-1.	Fluorine	45-53	complement component 4B (Chido blood group)	Mus musculus	33-36
18407378-3	2009	Secondly, the o-carborane cage connected to quinazoline moiety at C-4 position through an ether linkage: 4-O-(o-carboran-1-ylmethyl)-2-methylquinazoline.	o-Carborane	14-25	complement component 4B (Chido blood group)	Mus musculus	66-69
18407378-3	2009	Secondly, the o-carborane cage connected to quinazoline moiety at C-4 position through an ether linkage: 4-O-(o-carboran-1-ylmethyl)-2-methylquinazoline.	Quinazolines	44-55	complement component 4B (Chido blood group)	Mus musculus	66-69
18407378-3	2009	Secondly, the o-carborane cage connected to quinazoline moiety at C-4 position through an ether linkage: 4-O-(o-carboran-1-ylmethyl)-2-methylquinazoline.	Ether	90-95	complement component 4B (Chido blood group)	Mus musculus	66-69
18407378-3	2009	Secondly, the o-carborane cage connected to quinazoline moiety at C-4 position through an ether linkage: 4-O-(o-carboran-1-ylmethyl)-2-methylquinazoline.	4-o-(o-carboran-1-ylmethyl)-2-methylquinazoline	105-152	complement component 4B (Chido blood group)	Mus musculus	66-69
16571104-5	2006	The activity of dihydroceramide:sphinganine C-4-hydroxylase was reconstituted with the purified FLAG-Des2, mb5 (the membrane form of cytochrome b5) and bovine erythrocyte membrane.	dihydroceramide	16-31	complement component 4B (Chido blood group)	Mus musculus	44-47
10929004-9	2000	The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc.	N-acetylgalactosaminuronic acid	32-38	complement component 4B (Chido blood group)	Mus musculus	10-13
16621983-8	2006	Although leukotriene C(4) was reported to restore migration of murine Mrp1-deficient DC, the effects of MRP1 inhibition on DC differentiation appeared to be independent of the leukotriene pathway.	Leukotrienes	9-20	complement component 4B (Chido blood group)	Mus musculus	21-25
15334410-6	2004	During infusion of [1-13C]glucose, labeling in C-4 glutamate (indicative of flux into the first half of the TCA cycle) could be detected with 15-min resolution.	[1-13c]glucose	19-33	complement component 4B (Chido blood group)	Mus musculus	47-50
15334410-6	2004	During infusion of [1-13C]glucose, labeling in C-4 glutamate (indicative of flux into the first half of the TCA cycle) could be detected with 15-min resolution.	Glutamic Acid	51-60	complement component 4B (Chido blood group)	Mus musculus	47-50
15334410-6	2004	During infusion of [1-13C]glucose, labeling in C-4 glutamate (indicative of flux into the first half of the TCA cycle) could be detected with 15-min resolution.	Trichloroacetic Acid	108-111	complement component 4B (Chido blood group)	Mus musculus	47-50
15334410-9	2004	A 2.5-fold increase was observed in C-4 glutamate labeling and C-3 and C-2 glutamate labeling could be monitored with 30-min resolution.	Glutamic Acid	40-49	complement component 4B (Chido blood group)	Mus musculus	36-39
14731113-1	2004	The C-4 hydroxylation of sphinganine and dihydroceramide is a rate-limiting reaction in the biosynthesis of phytosphingolipids.	safingol	25-36	complement component 4B (Chido blood group)	Mus musculus	4-7
14731113-1	2004	The C-4 hydroxylation of sphinganine and dihydroceramide is a rate-limiting reaction in the biosynthesis of phytosphingolipids.	dihydroceramide	41-56	complement component 4B (Chido blood group)	Mus musculus	4-7
14731113-1	2004	The C-4 hydroxylation of sphinganine and dihydroceramide is a rate-limiting reaction in the biosynthesis of phytosphingolipids.	phytosphingolipids	108-126	complement component 4B (Chido blood group)	Mus musculus	4-7
14731113-10	2004	These results suggest that MDES2 is the dihydroceramide C-4 hydroxylase responsible for the biosynthesis of enriched phytosphingoglycolipids in the microvillous membranes of intestinal epithelial cells.	phytosphingoglycolipids	117-140	complement component 4B (Chido blood group)	Mus musculus	56-59
16289480-0	2006	Structural-activity relationship study on C-4 carbon atom of the CB1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides.	Carbon	46-52	complement component 4B (Chido blood group)	Mus musculus	42-45
16289480-0	2006	Structural-activity relationship study on C-4 carbon atom of the CB1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides.	Rimonabant	80-88	complement component 4B (Chido blood group)	Mus musculus	42-45
16289480-0	2006	Structural-activity relationship study on C-4 carbon atom of the CB1 antagonist SR141716: synthesis and pharmacological evaluation of 1,2,4-triazole-3-carboxamides.	1,2,4-triazole-3-carboxamide	134-163	complement component 4B (Chido blood group)	Mus musculus	42-45
16289480-3	2006	However, they showed only poor to moderate binding affinities, indicating that substitution of the C-4 pyrazole atom of the CB1 reference compound SR141716 by a nitrogen atom results in loss of affinity.	Rimonabant	147-155	complement component 4B (Chido blood group)	Mus musculus	99-102
16289480-3	2006	However, they showed only poor to moderate binding affinities, indicating that substitution of the C-4 pyrazole atom of the CB1 reference compound SR141716 by a nitrogen atom results in loss of affinity.	Nitrogen	161-169	complement component 4B (Chido blood group)	Mus musculus	99-102
12892650-9	2003	In older animals, PTZ-kindling decreased labeling in glutamate C-4 from [1-13C]glucose, whereas, in the younger mice, labeling in glutamine C-4 was decreased both from [1-13C]glucose and [1,2-13C]acetate.	Pentylenetetrazole	18-21	complement component 4B (Chido blood group)	Mus musculus	63-66
12892650-9	2003	In older animals, PTZ-kindling decreased labeling in glutamate C-4 from [1-13C]glucose, whereas, in the younger mice, labeling in glutamine C-4 was decreased both from [1-13C]glucose and [1,2-13C]acetate.	[1-13c	72-78	complement component 4B (Chido blood group)	Mus musculus	63-66
12892650-9	2003	In older animals, PTZ-kindling decreased labeling in glutamate C-4 from [1-13C]glucose, whereas, in the younger mice, labeling in glutamine C-4 was decreased both from [1-13C]glucose and [1,2-13C]acetate.	Glucose	79-86	complement component 4B (Chido blood group)	Mus musculus	63-66
12892650-9	2003	In older animals, PTZ-kindling decreased labeling in glutamate C-4 from [1-13C]glucose, whereas, in the younger mice, labeling in glutamine C-4 was decreased both from [1-13C]glucose and [1,2-13C]acetate.	13c	75-78	complement component 4B (Chido blood group)	Mus musculus	63-66
12892650-9	2003	In older animals, PTZ-kindling decreased labeling in glutamate C-4 from [1-13C]glucose, whereas, in the younger mice, labeling in glutamine C-4 was decreased both from [1-13C]glucose and [1,2-13C]acetate.	Glucose	175-182	complement component 4B (Chido blood group)	Mus musculus	140-143
12892650-9	2003	In older animals, PTZ-kindling decreased labeling in glutamate C-4 from [1-13C]glucose, whereas, in the younger mice, labeling in glutamine C-4 was decreased both from [1-13C]glucose and [1,2-13C]acetate.	[1,2-13c]acetate	187-203	complement component 4B (Chido blood group)	Mus musculus	140-143
12465029-1	2002	Five protected analogues of beta-D-galactosyl-(5R)-5-hydroxy-L-lysine were prepared, in which the galactosyl moiety was modified by monodeoxygenation or inversion of stereochemistry at C-4.	beta-d-galactosyl-(5r)-5-hydroxy-l-lysine	28-69	complement component 4B (Chido blood group)	Mus musculus	185-188
10929004-9	2000	The axial C-4 hydroxyl group of GalNAc interacted with IgG anti-TFD antibody, as evidenced by the lack of inhibitory activity of GlcNAc in contrast to GalNAc.	N-acetylgalactosaminuronic acid	151-157	complement component 4B (Chido blood group)	Mus musculus	10-13
9459571-16	1998	The structure/activity relationship shows that alkaloids that activate or block Na+ channels have a benzoyl ester side chain in the C-14 or C-4 positions respectively, whereas the other compounds lack this group.	Alkaloids	47-56	complement component 4B (Chido blood group)	Mus musculus	140-143
10579834-1	1999	A series of 8-cyanopyrido[3",2":4,5]thieno[3,2-d]-1,2,3-triazines, substituted at C-4 and C-7, were synthesized and evaluated as nitric oxide and prostaglandin E(2) inhibitors in murine peritoneal macrophages stimulated with bacterial endotoxin.	8-cyanopyrido[3",2":4,5]thieno[3,2-d]-1,2,3-triazines	12-65	complement component 4B (Chido blood group)	Mus musculus	82-85
9459571-16	1998	The structure/activity relationship shows that alkaloids that activate or block Na+ channels have a benzoyl ester side chain in the C-14 or C-4 positions respectively, whereas the other compounds lack this group.	benzoyl ester	100-113	complement component 4B (Chido blood group)	Mus musculus	140-143
9036388-4	1996	by applying classical synthetic methods to construct the aryl-hydrazone unit at C-4 of the heterocyclic system.	aryl-hydrazone	57-71	complement component 4B (Chido blood group)	Mus musculus	80-83
8568825-6	1996	This reversal of the ester function produced some new DAG mimetics that are embedded in a C-4 doubly-branched heptono-1,4-lactone template.	Diglycerides	54-57	complement component 4B (Chido blood group)	Mus musculus	90-93
9064288-6	1996	Both affinity purified (C4b Sepharose) and chromatographically isolated (using jacqualine agarose) sgp 120 were recognized by B1.9.E-2.	Sepharose	28-37	complement component 4B (Chido blood group)	Mus musculus	24-27
8568825-6	1996	This reversal of the ester function produced some new DAG mimetics that are embedded in a C-4 doubly-branched heptono-1,4-lactone template.	Esters	21-26	complement component 4B (Chido blood group)	Mus musculus	90-93
8568825-6	1996	This reversal of the ester function produced some new DAG mimetics that are embedded in a C-4 doubly-branched heptono-1,4-lactone template.	4-Butyrolactone	118-129	complement component 4B (Chido blood group)	Mus musculus	90-93
8983912-5	1996	Ebastine was shown to block the release of anti-IgE-induced prostaglandin D2 (PGD2) and leukotriene C4/D4 from human nasal polyp cells (IC30 values of 2.57 and 9.6 mumol/L, respectively) and to inhibit the release of cytokines.	ebastine	0-8	complement component 4B (Chido blood group)	Mus musculus	100-105
7760058-6	1995	From the C-3/C-4 labeling ratios in glutamine and glutamate and from the corresponding C-3/C-2 labeling ratio in GABA obtained with [2-13C]acetate, it was concluded that the carbon skeleton of glutamine to some extent was passed through TCA cycles before glutamate and GABA were formed.	Carbon	174-180	complement component 4B (Chido blood group)	Mus musculus	13-16
7760058-9	1995	Injection of [2-13C]acetate led to a higher 13C enrichment of the C-2 in glutamate and of the corresponding C-4 in GABA than in the C-3 of either compound.	[2-13c]acetate	13-27	complement component 4B (Chido blood group)	Mus musculus	108-111
7760058-9	1995	Injection of [2-13C]acetate led to a higher 13C enrichment of the C-2 in glutamate and of the corresponding C-4 in GABA than in the C-3 of either compound.	13c	16-19	complement component 4B (Chido blood group)	Mus musculus	108-111
7760058-9	1995	Injection of [2-13C]acetate led to a higher 13C enrichment of the C-2 in glutamate and of the corresponding C-4 in GABA than in the C-3 of either compound.	gamma-Aminobutyric Acid	115-119	complement component 4B (Chido blood group)	Mus musculus	108-111
8387597-2	1993	Twenty-two new ryanoids are described in which the C-4, C-12 bond is ruptured or replaced with an oxygen bridge and in which substituents at C-4 and C-12 are modified to have a wide range of polarities.	ryanoids	15-23	complement component 4B (Chido blood group)	Mus musculus	51-54
7647701-16	1994	During normoxia the labeling ratios in the C-2/C-4 positions in glutamine and in the equivalent positions in citrate were 0.27 and 0.11, respectively.	Glutamine	64-73	complement component 4B (Chido blood group)	Mus musculus	47-50
8387597-2	1993	Twenty-two new ryanoids are described in which the C-4, C-12 bond is ruptured or replaced with an oxygen bridge and in which substituents at C-4 and C-12 are modified to have a wide range of polarities.	ryanoids	15-23	complement component 4B (Chido blood group)	Mus musculus	141-144
8387597-4	1993	Structures of the new compounds are distinguished by changes in NMR chemical shifts of 13C and 1H nuclei in the regions of C-4 and C-12.	13c	87-90	complement component 4B (Chido blood group)	Mus musculus	123-126
8387597-4	1993	Structures of the new compounds are distinguished by changes in NMR chemical shifts of 13C and 1H nuclei in the regions of C-4 and C-12.	Hydrogen	95-97	complement component 4B (Chido blood group)	Mus musculus	123-126
8387597-4	1993	Structures of the new compounds are distinguished by changes in NMR chemical shifts of 13C and 1H nuclei in the regions of C-4 and C-12.	Carbon	89-90	complement component 4B (Chido blood group)	Mus musculus	123-126
1791470-1	1991	Synthesis of (+)-colartin, (+)-arbusculin A, and their C-4 epimers and their biological activities.	colartin	13-25	complement component 4B (Chido blood group)	Mus musculus	55-58
1740458-5	1992	We also show that formation of the covalently linked C4b.C3b complex occurs in the mouse complement system and that the C3b-binding site on mouse C4b is Ser at position 1213 which is homologous to Ser-1217 of human C4.	Serine	153-156	complement component 4B (Chido blood group)	Mus musculus	53-56
1740458-5	1992	We also show that formation of the covalently linked C4b.C3b complex occurs in the mouse complement system and that the C3b-binding site on mouse C4b is Ser at position 1213 which is homologous to Ser-1217 of human C4.	Serine	153-156	complement component 4B (Chido blood group)	Mus musculus	146-149
1740458-5	1992	We also show that formation of the covalently linked C4b.C3b complex occurs in the mouse complement system and that the C3b-binding site on mouse C4b is Ser at position 1213 which is homologous to Ser-1217 of human C4.	Serine	197-200	complement component 4B (Chido blood group)	Mus musculus	53-56
1740458-5	1992	We also show that formation of the covalently linked C4b.C3b complex occurs in the mouse complement system and that the C3b-binding site on mouse C4b is Ser at position 1213 which is homologous to Ser-1217 of human C4.	Serine	197-200	complement component 4B (Chido blood group)	Mus musculus	146-149
1740153-8	1992	L2 and L4 were monosulfated at C-6 and C-4 of the GalNAc residue, respectively.	N-acetylgalactosaminuronic acid	50-56	complement component 4B (Chido blood group)	Mus musculus	39-42
1293935-1	1992	As a continuing part of our study on the chemistry and antitumor activity of podophyllotoxin, 11 new C-4 S-substituted podophyllotoxin derivatives were synthesised and screened in vitro against L1210 leukemia and KB cells.	Podophyllotoxin	77-92	complement component 4B (Chido blood group)	Mus musculus	101-104
1293935-1	1992	As a continuing part of our study on the chemistry and antitumor activity of podophyllotoxin, 11 new C-4 S-substituted podophyllotoxin derivatives were synthesised and screened in vitro against L1210 leukemia and KB cells.	Podophyllotoxin	119-134	complement component 4B (Chido blood group)	Mus musculus	101-104
2009583-3	1991	7-Cl-BA and 7-Br-BA were metabolized considerably at C-3 and C-4, C-5 and C-6, C-8 and C-9, and C-10 and C-11.	7-chlorobenz(a)anthracene	0-7	complement component 4B (Chido blood group)	Mus musculus	61-64
2009583-3	1991	7-Cl-BA and 7-Br-BA were metabolized considerably at C-3 and C-4, C-5 and C-6, C-8 and C-9, and C-10 and C-11.	7-bromobenzanthracene	12-19	complement component 4B (Chido blood group)	Mus musculus	61-64
1900533-3	1991	The 1H NMR chemical shift of the C-4 hydrogen of pravadoline in comparison to the deshielding seen with 50, which lacks a substituent at C-2, suggested that the carbonyl group of pravadoline is located near C-2 but is located near C-4 in 50.	Hydrogen	37-45	complement component 4B (Chido blood group)	Mus musculus	33-36
1900533-3	1991	The 1H NMR chemical shift of the C-4 hydrogen of pravadoline in comparison to the deshielding seen with 50, which lacks a substituent at C-2, suggested that the carbonyl group of pravadoline is located near C-2 but is located near C-4 in 50.	pravadoline	49-60	complement component 4B (Chido blood group)	Mus musculus	33-36
1900533-3	1991	The 1H NMR chemical shift of the C-4 hydrogen of pravadoline in comparison to the deshielding seen with 50, which lacks a substituent at C-2, suggested that the carbonyl group of pravadoline is located near C-2 but is located near C-4 in 50.	pravadoline	179-190	complement component 4B (Chido blood group)	Mus musculus	33-36
1900533-3	1991	The 1H NMR chemical shift of the C-4 hydrogen of pravadoline in comparison to the deshielding seen with 50, which lacks a substituent at C-2, suggested that the carbonyl group of pravadoline is located near C-2 but is located near C-4 in 50.	pravadoline	179-190	complement component 4B (Chido blood group)	Mus musculus	231-234
2825816-6	1988	These studies demonstrated that the synthesis of leukotriene C4, leukotriene B4 and HETE in macrophages is differentially affected by DHA and EPA.	Eicosapentaenoic Acid	142-145	complement component 4B (Chido blood group)	Mus musculus	61-79
1900533-3	1991	The 1H NMR chemical shift of the C-4 hydrogen of pravadoline in comparison to the deshielding seen with 50, which lacks a substituent at C-2, suggested that the carbonyl group of pravadoline is located near C-2 but is located near C-4 in 50.	Hydrogen	4-6	complement component 4B (Chido blood group)	Mus musculus	33-36
2158873-4	1990	Leukemic livers also formed glutamine and glutamate labeled at the C-4 position.	Glutamine	28-37	complement component 4B (Chido blood group)	Mus musculus	67-70
2158873-4	1990	Leukemic livers also formed glutamine and glutamate labeled at the C-4 position.	Glutamic Acid	42-51	complement component 4B (Chido blood group)	Mus musculus	67-70
2979714-7	1988	The rate constant determined for deacylation of DAS at C-4 for this isoenzyme is 130-1000 times greater than that of the other carboxylesterases.	diacetoxyscirpenol	48-51	complement component 4B (Chido blood group)	Mus musculus	55-58
2454175-9	1988	The Asp in C4-A and His in C4-B seem likely to be the major specificity-defining residues.	Aspartic Acid	4-7	complement component 4B (Chido blood group)	Mus musculus	27-31
2454175-9	1988	The Asp in C4-A and His in C4-B seem likely to be the major specificity-defining residues.	Histidine	20-23	complement component 4B (Chido blood group)	Mus musculus	27-31
3124210-1	1987	The influence of lipopolysaccharide (LPS, endotoxin) or its lipid A component (bacterial and synthetic) on the synthesis of zymosan induced leukotriene C4, prostaglandin E2 and prostacyclin and on the conversion of exogenous arachidonic acid was studied in mouse peritoneal macrophages.	Zymosan	124-131	complement component 4B (Chido blood group)	Mus musculus	152-172
7310817-1	1981	Hydrogenolysis of 3-(benzyloxy)cyclophosphamide (10) using Pd/C catalyst and ethyl acetate as solvent leads to the formation of 3-hydroxycyclophosphamide (3, approximately 20%) and cyclophosphamide (1, approximately 10%), accompanied by regioselective hydrogen-exchange reactions at the C-4 and C-5 positions in 3 and 1.	Cyclophosphamide	31-47	complement component 4B (Chido blood group)	Mus musculus	287-290
6420398-6	1984	However, the reverse structure, in which the D-glucuronosyl moiety is bound at C-1 to an N-sulfated residue and at C-4 to N-acetylated glucosamine, is not a substrate.	Glucosamine	135-146	complement component 4B (Chido blood group)	Mus musculus	115-118
6440758-7	1984	The polysaccharide chains carry sulphate residues predominantly attached to C-4 of the galactosamine unit.	Polysaccharides	4-18	complement component 4B (Chido blood group)	Mus musculus	76-79
6440758-7	1984	The polysaccharide chains carry sulphate residues predominantly attached to C-4 of the galactosamine unit.	Galactosamine	87-100	complement component 4B (Chido blood group)	Mus musculus	76-79
6602183-3	1983	DTT-treated cells lost about 70% of the gamma-chain and over 95% of C4b activity; there was no loss of alpha" and beta chains or the ability to react with anti-C4 antibody.	Dithiothreitol	0-3	complement component 4B (Chido blood group)	Mus musculus	68-71
6243065-8	1983	Inspection of Dreiding models showed that the oxygens on C-27, C-3, and C-30 of aplysiatoxin are aligned with the oxygens on C-3, C-4, and C-20 of TPA, respectively.	Oxygen	46-53	complement component 4B (Chido blood group)	Mus musculus	130-133
6243065-8	1983	Inspection of Dreiding models showed that the oxygens on C-27, C-3, and C-30 of aplysiatoxin are aligned with the oxygens on C-3, C-4, and C-20 of TPA, respectively.	Oxygen	114-121	complement component 4B (Chido blood group)	Mus musculus	130-133
6243065-8	1983	Inspection of Dreiding models showed that the oxygens on C-27, C-3, and C-30 of aplysiatoxin are aligned with the oxygens on C-3, C-4, and C-20 of TPA, respectively.	Tetradecanoylphorbol Acetate	147-150	complement component 4B (Chido blood group)	Mus musculus	130-133
3722187-4	1986	The site of truncation of the alpha-chain of C4 in plasma was established by sequence analysis of the COOH-terminal cyanogen bromide fragment isolated by high performance liquid chromatography.	Cyanogen Bromide	116-132	complement component 4B (Chido blood group)	Mus musculus	45-47
4055755-3	1985	The glycosaminoglycan chains carry sulfate residues predominantly attached to C-4 of the galactosamine unit; less than 10% of the sulfate groups occur as 6-sulfated galactosamine units.	Glycosaminoglycans	4-21	complement component 4B (Chido blood group)	Mus musculus	78-81
4055755-3	1985	The glycosaminoglycan chains carry sulfate residues predominantly attached to C-4 of the galactosamine unit; less than 10% of the sulfate groups occur as 6-sulfated galactosamine units.	Sulfates	35-42	complement component 4B (Chido blood group)	Mus musculus	78-81
7182841-5	1982	A good solubility-activity relationship depending on bromine substituents at C-4 and C-5 in the pyridazine-3, 6-dione group was observed.	Bromine	53-60	complement component 4B (Chido blood group)	Mus musculus	77-80
7182841-5	1982	A good solubility-activity relationship depending on bromine substituents at C-4 and C-5 in the pyridazine-3, 6-dione group was observed.	pyridazine-3, 6-dione	96-117	complement component 4B (Chido blood group)	Mus musculus	77-80
7182841-6	1982	The activity of soluble, pyridazine-3,6-diones depended proportionally on the number of bromine substituents at C-4 and C-5 -contrary to solubility inversely proportional to the number of bromine atoms.	pyridazine-3,6-diones	25-46	complement component 4B (Chido blood group)	Mus musculus	112-115
7182841-6	1982	The activity of soluble, pyridazine-3,6-diones depended proportionally on the number of bromine substituents at C-4 and C-5 -contrary to solubility inversely proportional to the number of bromine atoms.	Bromine	88-95	complement component 4B (Chido blood group)	Mus musculus	112-115
7310817-1	1981	Hydrogenolysis of 3-(benzyloxy)cyclophosphamide (10) using Pd/C catalyst and ethyl acetate as solvent leads to the formation of 3-hydroxycyclophosphamide (3, approximately 20%) and cyclophosphamide (1, approximately 10%), accompanied by regioselective hydrogen-exchange reactions at the C-4 and C-5 positions in 3 and 1.	3-(benzyloxy)cyclophosphamide	18-47	complement component 4B (Chido blood group)	Mus musculus	287-290
7310817-1	1981	Hydrogenolysis of 3-(benzyloxy)cyclophosphamide (10) using Pd/C catalyst and ethyl acetate as solvent leads to the formation of 3-hydroxycyclophosphamide (3, approximately 20%) and cyclophosphamide (1, approximately 10%), accompanied by regioselective hydrogen-exchange reactions at the C-4 and C-5 positions in 3 and 1.	ethyl acetate	77-90	complement component 4B (Chido blood group)	Mus musculus	287-290
7310817-1	1981	Hydrogenolysis of 3-(benzyloxy)cyclophosphamide (10) using Pd/C catalyst and ethyl acetate as solvent leads to the formation of 3-hydroxycyclophosphamide (3, approximately 20%) and cyclophosphamide (1, approximately 10%), accompanied by regioselective hydrogen-exchange reactions at the C-4 and C-5 positions in 3 and 1.	3-hydroxycyclophosphamide	128-153	complement component 4B (Chido blood group)	Mus musculus	287-290
7439958-4	1980	Comparison of tryptic peptide profiles of radiolabeled C4 beta-chains encoded by different S regions revealed differences in their primary structures.	Peptides	22-29	complement component 4B (Chido blood group)	Mus musculus	55-62
7451556-0	1980	Relationship between ornithine decarboxylase-inducing activity and configuration at C-4 in phorbol ester derivatives.	Phorbol Esters	91-104	complement component 4B (Chido blood group)	Mus musculus	84-87
647696-5	1978	The results show that anthracycline derivatives characterized by the absence of the methoxyl group at the C-4 position are markedly more potent than the parent compound, and may exhibit a differential antitumor effect on a number of mouse tumors.	Anthracyclines	22-35	complement component 4B (Chido blood group)	Mus musculus	106-109
7288819-1	1981	One of the major biotransformation pathways in the metabolism of phencyclidine is hydroxylation at C-4 of the cyclohexane ring to give 4-phenyl-4-(1-piperidinyl)cyclohexanol (1).	Phencyclidine	65-78	complement component 4B (Chido blood group)	Mus musculus	99-102
7288819-1	1981	One of the major biotransformation pathways in the metabolism of phencyclidine is hydroxylation at C-4 of the cyclohexane ring to give 4-phenyl-4-(1-piperidinyl)cyclohexanol (1).	Cyclohexane	110-121	complement component 4B (Chido blood group)	Mus musculus	99-102
7288819-1	1981	One of the major biotransformation pathways in the metabolism of phencyclidine is hydroxylation at C-4 of the cyclohexane ring to give 4-phenyl-4-(1-piperidinyl)cyclohexanol (1).	4-phenyl-4-piperidinocyclohexanol	135-173	complement component 4B (Chido blood group)	Mus musculus	99-102
7357569-0	1980	Modifications at C-3 and C-4 of 2-amino-2-deoxy-D-glucose.	Glucosamine	32-57	complement component 4B (Chido blood group)	Mus musculus	25-28
7357569-1	1980	Modifications at C-3 and C-4 of 2-amino-2-deoxy-D-glucose have been developed.	Glucosamine	32-57	complement component 4B (Chido blood group)	Mus musculus	25-28
762433-6	1979	The complexes were dissociated at high salt concentration, and the C4 fragments were isolated by passage of the mixture through a second Sephadex G-200 column.	sephadex	137-151	complement component 4B (Chido blood group)	Mus musculus	67-69
23087055-4	2012	Using crude membranes in an ABCC10 overexpression system, we found that the ABCC10 transport substrates estrogen estradiol-glucuronide (E(2)17betaG) and leukotriene C4 (LTC(4)) significantly stimulated ABCC10 beryllium fluoride (BeFx)-sensitive ATPase activity.	beryllium fluoride	209-227	complement component 4B (Chido blood group)	Mus musculus	165-175
408488-4	1977	Whereas the pethidine and prodine analgesics have quaternary phenyl substituion at C-4 of the piperidine ring, compound 7 does not.	Meperidine	12-21	complement component 4B (Chido blood group)	Mus musculus	83-86
25982331-1	2015	Combination of the Suzuki cross-coupling and nucleophilic aromatic substitution of hydrogen (SN(H)) reactions proved to be a convenient method for the synthesis of C(4) and/or C(5) mono(thienyl) and di(thienyl) substituted pyrimidines from commercially available 5-bromopyrimidine.	Hydrogen	83-91	complement component 4B (Chido blood group)	Mus musculus	164-168
25982331-1	2015	Combination of the Suzuki cross-coupling and nucleophilic aromatic substitution of hydrogen (SN(H)) reactions proved to be a convenient method for the synthesis of C(4) and/or C(5) mono(thienyl) and di(thienyl) substituted pyrimidines from commercially available 5-bromopyrimidine.	sn(h)	93-98	complement component 4B (Chido blood group)	Mus musculus	164-168
25982331-1	2015	Combination of the Suzuki cross-coupling and nucleophilic aromatic substitution of hydrogen (SN(H)) reactions proved to be a convenient method for the synthesis of C(4) and/or C(5) mono(thienyl) and di(thienyl) substituted pyrimidines from commercially available 5-bromopyrimidine.	5-bromopyrimidine	263-280	complement component 4B (Chido blood group)	Mus musculus	164-168
24224693-1	2013	After extensive synthetic efforts, we found that many structurally diverse bioisosteres could be generated via derivatizing the C-4 alkyl chain on the pyrazole ring of compound 3 (B/P = 1/33) with different electronegative groups.	pyrazole	151-159	complement component 4B (Chido blood group)	Mus musculus	128-131
408488-4	1977	Whereas the pethidine and prodine analgesics have quaternary phenyl substituion at C-4 of the piperidine ring, compound 7 does not.	Alphaprodine	26-33	complement component 4B (Chido blood group)	Mus musculus	83-86
408488-4	1977	Whereas the pethidine and prodine analgesics have quaternary phenyl substituion at C-4 of the piperidine ring, compound 7 does not.	piperidine	94-104	complement component 4B (Chido blood group)	Mus musculus	83-86
917013-0	1977	Increase of phagocytic activity and new appearance of a C4b (guinea pig) recognizing capability in peritoneal macrophages from Corynebacterium parvum and thioglycollate-stimulated mice.	Thioglycolates	154-168	complement component 4B (Chido blood group)	Mus musculus	56-59
23523259-12	2013	The location of glycoside at C-3 for borapetoside A but C-6 for borapetoside C and the formation of lactone between C-4 and C-6 for borapetoside A, could account for the different potency in hypoglycemic action for these two compounds.	Lactones	100-107	complement component 4B (Chido blood group)	Mus musculus	116-119
23523259-12	2013	The location of glycoside at C-3 for borapetoside A but C-6 for borapetoside C and the formation of lactone between C-4 and C-6 for borapetoside A, could account for the different potency in hypoglycemic action for these two compounds.	borapetoside A	132-146	complement component 4B (Chido blood group)	Mus musculus	116-119
23442682-2	2012	The polygalacturonic acid (AE-CWI) contained 95% GalA and its (13)C NMR spectrum showed signals at delta 98.9, 78.0, 71.4, 69.1, 68.4, and 175.1 from C-1, C-4, C-5, C-3, C-2, and C-6 respectively, from (1 4)-linked alpha-GalpA units.	polygalacturonic acid	4-25	complement component 4B (Chido blood group)	Mus musculus	155-158
23442682-2	2012	The polygalacturonic acid (AE-CWI) contained 95% GalA and its (13)C NMR spectrum showed signals at delta 98.9, 78.0, 71.4, 69.1, 68.4, and 175.1 from C-1, C-4, C-5, C-3, C-2, and C-6 respectively, from (1 4)-linked alpha-GalpA units.	ae-cwi	27-33	complement component 4B (Chido blood group)	Mus musculus	155-158
21986639-2	2011	These compounds embed an isomeric substitution pattern resulting from a formal permutation of the C-2 and C-4 substituents along the aliphatic skeleton of the original sphingoid base.	sphingoid base	168-182	complement component 4B (Chido blood group)	Mus musculus	106-109